SEARCH

SEARCH BY CITATION

References

  • Arts, E.J. and Hazuda, D.J. (2012) HIV-1 Antiretroviral Drug Therapy. Cold Spring Harb. Perspect. Med. 2, a007161.
  • Barbaro, G. (2006) Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr. HIV Res. 4, 7985.
  • Barbaro, G., Scozzafava, A., Mastrolorenzo, A. and Supuran, C.T. (2005) Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. 11, 18051843.
  • Bartlett, J.G. (2006) Ten Years of HAART: Foundation for the Future. http://www.medscape.org/viewarticle/523119. (accessed 03 April 2013).
  • Batard, Y., Hehn, A., Nedelkina, S., Schalk, M., Pallett, K., Schaller, H. and Werck-Reichhart, D. (2000) Increasing expression of P450 and P450-reductase proteins from monocots in heterologous systems. Arch. Biochem. Biophys. 379, 161169.
  • Beck, A., Wurch, T., Bailly, C. and Corvaia, N. (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10, 345352.
  • Caragea, C., Sinapov, J., Silvescu, A., Dobbs, D. and Honavar, V. (2007) Glycosylation site prediction using ensembles of Support Vector Machine classifiers. BMC Bioinformatics, 8, 438.
  • Castilho, A. and Steinkellner, H. (2012) Glyco-engineering in plants to produce human-like N-glycan structures. Biotechnol. J. 7, 10881098.
  • Castilho, A., Neumann, L., Gattinger, P., Strasser, R., Vorauer-Uhl, K., Sterovsky, T., Altmann, F. and Steinkellner, H. (2013) Generation of biologically active multi-sialylated recombinant human EPOFc in plants. PLoS ONE, 8, e54836.
  • Chen, W., Ying, T. and Dimitrov, D.S. (2013) Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design. Expert Opin. Biol. Ther. 13, 115.
  • Colgan, R., Atkinson, C.J., Paul, M.J., Hassan, S., Drake, P.M., Sexton, A.L., Santa-Cruz, S., James, D., Hamp, K., Gutteridge, C. and Ma, J.K.C. (2010) Optimization of contained Nicotiana tabacum cultivation for the production of recombinant protein pharmaceuticals. Transgenic Res. 19, 241256.
  • Desai, P.N., Shrivastava, N. and Padh, H. (2010) Production of heterologous proteins in plants: strategies for optimal expression. Biotechnol. Adv. 28, 427435.
  • Doria-Rose, N.A., Klein, R.M., Daniels, M.G., O'Dell, S., Nason, M., Lapedes, A., Bhattacharya, T., Migueles, S.A., Wyatt, R.T., Korber, B.T., Mascola, J.R. and Connors, M. (2010) Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84, 16311636.
  • Edney, A. (2013) Protalix Wins FDA Approval for Its First Drug on the Market. http://www.bloomberg.com/news/2012-05-01/protalix-wins-fda-approval-for-its-first-drug-on-the-market.html. (accessed 04 March 2013).
  • EMEA. (2008) Guideline on the Quality of Biological Active Substance Produced by Stable Transgene Expression in Higher Plants EMA. London, UK: EMEA Committee for Proprietary Medicinal Products (CPMP).
  • Fischer, R., Schillberg, S., Hellwig, S., Twyman, R.M. and Drossard, J. (2012) GMP issues for recombinant plant-derived pharmaceutical proteins. Biotechnol. Adv. 30, 434439.
  • Floss, D.M., Sack, M., Arcalis, E., Stadlmann, J., Quendler, H., Rademacher, T., Stoger, E., Scheller, J., Fischer, R. and Conrad, U. (2009) Influence of elastin-like peptide fusions on the quantity and quality of a tobacco-derived human immunodeficiency virus-neutralizing antibody. Plant Biotechnol. J. 7, 899913.
  • Forthal, D.N., Gach, J.S., Landucci, G., Jez, J., Strasser, R., Kunert, R. and Steinkellner, H. (2010) Fc-Glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J. Immunol. 185, 68766882.
  • Gleba, Y., Klimyuk, V. and Marillonnet, S. (2007) Viral vectors for the expression of proteins in plants. Curr. Opin. Biotechnol. 18, 134141.
  • Hamorsky, K.T., Grooms-Williams, T.W., Husk, A.S., Bennett, L.J., Palmer, K.E. and Matoba, N. (2013) Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana plants and its utility in combination microbicides. Antimicrob. Agents Chemother. 57, 20762086.
  • Hehle, V.K., Paul, M.J., Drake, P.M., Ma, J.K.C. and van Dolleweerd, C.J. (2011) Antibody degradation in tobacco plants: a predominantly apoplastic process. BMC Biotechnol. 11, 128.
  • Hiatt, A., Caffferkey, R. and Bowdish, K. (1989) Production of antibodies in plants. Nature, 342, 7678.
  • Hood, E.E., Woodard, S.L. and Horn, M.E. (2002) Monoclonal antibody manufacturing in transgenic plants — myths and realities. Curr. Opin. Biotechnol. 13, 630635.
  • Horsch, R.B., Fry, J.E., Hoffmann, N.L., Eichholtz, D., Rogers, S.G. and Fraley, R.T. (1985) A simple and general method for transferring genes into plants. Science, 227, 12291231.
  • Kapila, J., De Rycke, R., Van Montagu, M. and Angenon, G. (1997) An Agrobacterium-mediated transient gene expression system for intact leaves. Plant Sci. 122, 101108.
  • Kelley, B. (2009) Industrialization of mAb production technology the bioprocessing industry at a crossroads. mAbs, 1, 443452.
  • Klein, F., Halper-Stromberg, A., Horwitz, J.A., Halper-Stromberg, A., Scheid, J.F., Bournazos, S., Mouquet, H., Spatz, L.A., Diskin, R., Abadir, A., Zang, T., Dorner, M., Billerbeck, E., Labitt, R.N., Gaebler, C., Marcovecchio, P.M., Incesu, R.-B., Eisenreich, T.R., Bieniasz, P.D., Seaman, M.S., Bjorkman, P.J., Ravetch, J.V., Ploss, A. and Nussenzweig, M.C. (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature, 492, 118122.
  • Li, M., Gao, F., Mascola, J.R., Stamatatos, L., Polonis, V.R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K.M., Bilska, M., Kothe, D.L., Salazar-Gonzalez, J.F., Wei, X., Decker, J.M., Hahn, B.H. and Montefiori, D.C. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 1010810125.
  • Li, Y., Migueles, S.A., Welcher, B., Svehla, K., Phogat, A., Louder, M.K., Wu, X., Shaw, G.M., Connors, M., Wyatt, R.T. and Mascola, J.R. (2007) Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13, 10321034.
  • Li, Y., Svehla, K., Louder, M.K., Wycuff, D., Phogat, S., Min, T., Migueles, S.A., Wu, X., Phogat, A., Shaw, G.M., Connors, M., Hoxie, J., Mascola, J.R. and Wyatt, R.T. (2009) Analysis of neutralization specificities in polyclonal sera derived from HUMAN immunodeficiency virus type 1-infected individuals. J. Virol. 83, 10451059.
  • Lopez, J.C., Khamsi, R., Dolgin, E., Grigoryev, Y., Jiang, K., Pola, C., Swami, M., Aranda, V., Basson, M., Chmielnicki, E., Da Silva, K., Farrell, A., Levinson, R., Boettner, B. and Gershon, D. (eds). (2013) Prevention measures. Nat. Med. 19, 247.
  • Marillonnet, S., Giritch, A., Gils, M., Kandzia, R., Klimyuk, V. and Gleba, Y. (2005) In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc. Natl Acad. Sci. USA, 101, 68526857.
  • May, M.T. and Ingle, S.M. (2011) Life expectancy of HIV-positive adults: a review. Sex. Health, 8, 526533.
  • Montefiori, D.C. (2004) Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. In: Current Protocols in Immunology, (Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W. and Coico, R., eds), pp. 12.11.112.11.15. New York, NY: John Wiley & Sons.
  • Murashige, T. and Skoog, F. (1962) A revised medium for rapid growth and bioassays with tobacco culture. Physiol. Plant. 15, 473497.
  • Nuttall, J., Vine, N., Hadlington, J.L., Drake, P., Frigerio, L. and Ma, J.K.C. (2002) ER–resident chaperone interactions with recombinant antibodies in transgenic plants. Eur. J. Biochem. 269, 60426051.
  • Overbaugh, J. and Morris, L. (2012) The antibody response against HIV-1. Cold Spring Harb. Perspec. Med. 2, a007039.
  • Pabst, M., Chang, M., Stadlmann, J. and Altmann, F. (2012) Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140. J. Biol. Chem. 393, 719730.
  • Pachl, J., Svoboda, P., Jacobs, F., Vandewoude, K., van der Hoven, B., Spronk, P., Masterson, G., Malbrain, M., Aoun, M., Garbino, J., Takala, J., Drgona, L., Burnie, J., Matthews, R. and Group, M.I.C.S. (2006) A Randomized, Blinded, Multicenter Trial of Lipid-Associated Amphotericin B Alone versus in Combination with an Antibody-Based Inhibitor of Heat Shock Protein 90 in Patients with Invasive Candidiasis. Clin. Infect. Dis. 42, 14041413.
  • Pegu, A., Yang, Z.-Y., Chen, X., Todd, J.-P., McKee, K., Rao, S., Mascola, J.R. and Nabel, G. (2011) VRC01 provides sterilizing protection to non human primates from mucosal SHIV challenges. J. Immunol. 186, 155.111.
  • Pirrone, V., Thakkar, N., Jacobson, J.M., Wigdahl, B. and Krebs, F.C. (2011) Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob. Agents Chemother. 55, 18311842.
  • Rosenberg, Y., Sack, M., Montefiori, D., Forthal, D., Mao, L., Hernandez-Abanto, S., Urban, L., Landucci, G., Fischer, R. and Jiang, X. (2013) Rapid high-level production of functional HIV broadly neutralizing monoclonal Antibodies in transient plant expression systems. PLoS ONE, 8, e58724.
  • Rouwendal, G.J.A., Mendes, O., Wolbert, E.J.H. and de Boer, D. (1997) Enhanced expression in tobacco of the gene encoding green fluorescent protein by modification of its codon usage. Plant Mol. Biol. 33, 989999.
  • Rusconi, S., Scozzafava, A., Mastrolorenzo, A. and Supuran, C.T. (2007) An update in the development of HIV entry inhibitors. Curr. Top. Med. Chem. 7, 12731289.
  • Sack, M., Paetz, A., Kunert, R., Bomble, M., Hesse, F., Stiegler, G., Fischer, R., Katinger, H., Stoeger, E. and Rademacher, T. (2007) Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures. FASEB J. 21, 16551664.
  • Sainsbury, F. and Lomonossoff, G. (2008) Extremely high-level and rapid transient protein production in plants without the use of viral replication. Plant Physiol. 148, 12121218.
  • Sainsbury, F., Thuenemann, E.C. and Lomonossoff, G.P. (2009) pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. Plant Biotechnol. J. 7, 682693.
  • Sainsbury, F., Sack, M., Stadlmann, J., Quendler, H., Fischer, R. and Lomonossoff, G.P. (2010) Rapid transient production in plants by replicating and non-replicating vectors yields high quality functional anti-HIV antibody. PLoS ONE, 5, e13976.
  • Scott, A.M., Wolchok, J.D. and Old, L.J. (2012) Antibody therapy of cancer. Nat. Rev. Cancer, 12, 278287.
  • Shattock, R.J. and Rosenberg, Z. (2012) Microbicides: topical prevention against HIV. Cold Spring Harb. Perspect. Med. 2, a007385.
  • Simek, M.D., Rida, W., Priddy, F.H., Pung, P., Carrow, E., Laufer, D.S., Lehrman, J.K., Boaz, M., Tarragona-Fiol, T., Miiro, G., Birungi, J., Pozniak, A., McPhee, D.A., Manigart, O., Karita, E., Inwoley, A., Jaoko, W., DeHovitz, J., Bekker, L.-G., Pitisuttithum, P., Paris, R., Walker, L.M., Poignard, P., Wrin, T., Fast, P.E., Burton, D.R. and Koff, W.C. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 73377348.
  • Strasser, R., Stadlmann, J., Schahs, M., Stiegler, G., Quendler, H., Mach, L., Glossl, J., Weterings, K., Pabst, M. and Steinkellner, H. (2008) Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 6, 392402.
  • Strasser, R., Castilho, A., Stadlmann, J., Kunert, R., Quendler, H., Gattinger, P., Jez, J., Rademacher, T., Altmann, F. and Mach, L. (2009) Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous β1, 4-galactosylated N-glycan profile. J. Biol. Chem. 284, 2047920485.
  • UN. (2011) Political Declaration on HIV/AIDS: Intensifying our Efforts to Eliminate HIV/AIDS. http://daccess-dds-ny.un.org/doc/UNDOC/LTD/N11/367/84/PDF/N1136784.pdf?OpenElement. (accessed 04 March 2012).
  • UNAIDS. (2012) Global Report: UNAIDS Report on the Global AIDS Epidemic 2012.
  • Veselinovic, M., Preston Neff, C., Mulder, L.R. and Akkina, R. (2012) Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology, 432, 505510.
  • Wadman, M. (2013) HIV trial under scrutiny. Nature, 493, 279280.
  • Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., Komarova, N.L., Nowak, M.A., Hahn, B.H., Kwong, P.D. and Shaw, G.M. (2003) Antibody neutralization and escape by HIV-1. Nature, 422, 307312.
  • WHO. (2006) Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. (Gilks, C. and Vitoria, A., eds), 128 pp. http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. (accessed 03 April 2013).
  • WHO. (2008) The Top 10 Causes of Death—WHO Fact Sheet No. 310. http://who.int/mediacentre/factsheets/fs310/en/. (accessed 03 April 2013).
  • WHO. (2012a) Antiretroviral Treatment as Prevention (TASP) of HIV and TB: Programmatic Update. http://whqlibdoc.who.int/hq/2012/WHO_HIV_2012.12_eng.pdf. (accessed 04 March 2013).
  • WHO (2012b) Guidance on Oral pre-Exposure prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women who have Sex with Men at High Risk of HIV.
  • WHO and ILO. (2007) Post-exposure Prophylaxis to Prevent HIV Infection: Joint WHO/ILO Guidelines on Post-exposure Prophylaxis (PEP) to Prevent HIV Infection.
  • WHO, UNAIDS and UNICEF. (2007) Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector (progress report). http://www.who.int/hiv/mediacentre/universal_access_progress_report_en.pdf. (accessed 04 March 2013).
  • Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou, T., Schmidt, S.D., Wu, L., Xu, L., Longo, N.S., McKee, K., O'Dell, S., Louder, M.K., Wycuff, D.L., Feng, Y., Nason, M., Doria-Rose, N., Connors, M., Kwong, P.D., Roederer, M., Wyatt, R.T., Nabel, G.J. and Mascola, J.R. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science, 329, 856861.
  • Zhou, T., Georgiev, I., Wu, X., Yang, Z.Y., Dai, K., Finzi, A., Kwon, Y.D., Scheid, J.F., Shi, W., Xu, L., Yang, Y., Zhu, J., Nussenzweig, M.C., Sodroski, J., Shapiro, L., Nabel, G.J., Mascola, J.R. and Kwong, P.D. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science, 329, 811817.